Anika Therapeutics (NASDAQ:ANIK) Issues FY 2021 Earnings Guidance

Anika Therapeutics (NASDAQ:ANIK) updated its FY 2021 earnings guidance on Tuesday. The company provided EPS guidance of $- for the period. The company issued revenue guidance of $143.50 million-147.42 million, compared to the consensus revenue estimate of $144.15 million.

Separately, Zacks Investment Research raised shares of Anika Therapeutics from a sell rating to a hold rating in a report on Thursday, May 6th.

Shares of ANIK stock traded down $1.07 on Friday, reaching $43.69. The stock had a trading volume of 2,557 shares, compared to its average volume of 129,933. The stock’s 50-day moving average price is $42.54. The stock has a market capitalization of $628.74 million, a price-to-earnings ratio of -23.68, a price-to-earnings-growth ratio of 24.26 and a beta of 1.21. Anika Therapeutics has a 12 month low of $31.55 and a 12 month high of $48.37.

Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings results on Wednesday, May 5th. The biotechnology company reported $0.20 EPS for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.19. Anika Therapeutics had a negative net margin of 20.83% and a negative return on equity of 0.98%. The business had revenue of $34.29 million for the quarter, compared to analyst estimates of $32.39 million. Equities analysts forecast that Anika Therapeutics will post 0.19 earnings per share for the current year.

In other Anika Therapeutics news, Director Raymond J. Land sold 2,000 shares of the stock in a transaction that occurred on Wednesday, May 12th. The shares were sold at an average price of $42.60, for a total transaction of $85,200.00. Following the transaction, the director now owns 7,953 shares in the company, valued at approximately $338,797.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.09% of the stock is currently owned by corporate insiders.

About Anika Therapeutics

Anika Therapeutics, Inc, together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses.

Further Reading: Bollinger Bands

Earnings History and Estimates for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with's FREE daily email newsletter.